Merck Sharp + Dohme Corp.

Eisai R&d Management Co., Ltd.

Alexion Pharmaceuticals, Inc.

Dynavax Technologies Corporation

Trisalus Life Sciences, Inc.

Surefire Medical, Inc.

Andrew Evan Denker

Robert A Kastelein

Robert L Coffman

Cristiana Guiducci

Kimiyo Tabata

Robert S Janssen

Yu Kato

Yusaku Hori

Uyen Truong Phan

Svetlana Sadekova

David Ross Kaufman

Ying Yu

Peter T Meinke

Xiang Gao

Rajendra Pradhan

Stephan Ortiz

Lori Payton

Marc Vallee

Gary E Meininger

Christian Mix

Eugene Scott Swenson

Steven Charnick

John A Wagner

Naoto Uemura

Wei-Jian Pan

Scott Edward Moseley

Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof, in pediatric patients.

Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein Ris Calkyl or Ccycloalkyl, Ris a hydrogen atom or Calkoxy, and Ris a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.

Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): 

Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., an adult having HPP, such as an adult having pediatric-onset HPP, or an adolescent having HPP) exhibiting decreased pyrophosphate (PPi) or pyridoxal 5'-phosphate (PLP) concentrations in, e.g., a plasma sample, physical impairments, or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.

Methods for treating hypophosphatasia (HPP) in adults and adolescents

Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

Fused aromatic compounds of Formula I are PPAR gamma agonists or partial agonists and are useful for weekly dosing in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. 

Method of treatment using fused aromatic compounds having anti-diabetic activity

Growing community of inventors

North Wales, PA, United States of America

Andrew Evan Denker